drugset / Trial / NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2
Recruiting
620 enrolled
Fudan University
Affiliated Hospital of Nantong University · collabChongqing University Cancer Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Hospital of China Medical University · collabFujian Medical University Union Hospital · collabLiaoning Cancer Hospital & Institute · collabNanchang People's Hospital · collabNingbo Medical Center Lihuili Hospital · collabNorthern Jiangsu People's Hospital · collabPeking University Cancer Hospital & Institute · collabShanghai 6th People's Hospital · collabShanghai First Maternity and Infant Hospital · collabSun Yat-sen University · collabThe First Hospital of Jilin University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
Timeline
- Start
- 2022-12-30
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg | Oral |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Dalpiciclib | Small molecule | 125 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Famitinib | Small molecule | 5 mg | Oral |
| Subject | Famitinib | Small molecule | 15 mg | Oral |
| Subject | Famitinib | Small molecule | 20 mg | Oral |
| Subject | Fluzoparib | Small molecule | 100 mg | Oral |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | SHR-1167 | Unknown | — | — |
| Subject | SHR-6209 | Unknown | — | — |
| Subject | SHR-A1921 | Monoclonal antibody | — | — |
| Subject | SHR-A2009 | Other / unclassified | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |
| Subject | Sorafenib | Small molecule | 0.4 g | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |
| Background | Anastrozole | Other / unclassified | 1 mg | Oral |
| Background | Capecitabine | Small molecule | — | — |
| Background | Exemestane | Small molecule | 25 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Background | Goserelin | Other / unclassified | 3.6 mg | Intramuscular |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Vinorelbine | Small molecule | — | — |
| Background | irbribulin | Unknown | — | — |